跳至主要内容
临床试验/NCT02060799
NCT02060799已完成不适用

European Dyspnoea Survey in the EMergency Departments

Hopital Lariboisière10 个研究点 分布在 10 个国家目标入组 2,156 人开始时间: 2014年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
2,156
试验地点
10
主要终点
All cause mortality

研究概览

简要总结

Braunwald defines dyspnoea as an abnormally uncomfortable awareness of breathing. Breathing discomfort, and its varying degrees of severity, is the one of the most disturbing symptoms patients can experience; and it is one of the main complaints in the patients presenting to the Emergency Department (ED). Dyspnea has a variety of underlying etiologies, like cardiac, pulmonary or metabolic etiologies or a combination of them, since several diseases can cause dyspnea like for instance heart failure (HF), asthma and chronic obstructive pulmonary disease (COPD).

Acute heart failure syndrome (AHFS) is collectively defined as a gradual or rapid change in heart failure (HF) signs and symptoms resulting in a need for urgent therapy. Heart failure (HF) is one of the most important causes of morbidity and mortality in the industrialized world. The prevalence of symptomatic HF is estimated to range from 0.4 to 2.0% in general European population. The incidence increases rapidly with age, and in Europe. Characteristics, clinical presentation, treatment, and outcomes of HF patients admitted to hospital have been adequately described, in Europe and in the United States. The Euro Heart Failure Survey (EHFS) I with 11 327 patients described the demographics of acutely hospitalized HF patients. The ADHERE registry has data on over 100 000 hospitalizations for AHF from the USA. In-hospital mortality was 4 and 7%, in ADHERE and EHFS I, respectively.

This same sensation of breathlessness is what also drives patients with asthma and chronic obstructive pulmonary disease (COPD) to the ED. Chronic obstructive pulmonary disease (COPD) exacerbation accounts for approximately 1.5 million ED visits in the United States per year. It is the third most common cause of hospitalization, with an estimated 726 000 hospitalizations in 2000 in the USA. Previous studies have demonstrated important differences between guideline recommendations and actual management of COPD exacerbation, either in the ED or during hospitalization.

The diagnosis in front of a dyspneic patient in the ED remains a challenge, because of a low sensitivity of the clinical signs associated with the aging of the population and the variety of underlying diseases. Little is known about the Epidemiology of dyspneic patients in the ED at the European level. Diagnosis, prevalence and treatment of the patients may vary among European countries.

详细描述

MAIN OBJECTIVES

  • Epidemiologic description of patients presenting to the ED with shortness of breath as main complaint.
  • Description of current management in the ED of patients presenting to the ED with shortness of breath as main complaint.

SECONDARY OBJECTIVES

  • Sub analysis of ED discharged patients versus admitted patients for characteristics, comparison to recommended care and re-ED visit.

  • Determine clinical and/or biological criteria to distinguish between:

  • Patients who are treated as outpatients and admitted patients.

  • Patients hospitalized in ward and patients admitted to intensive care units (CCU and ICU)

  • Prognostic prediction, using clinical and biochemical data

  • To determine if ED patients treated for acute heart failure differ from those admitted to hospital.

  • Comparison of European data characteristics, investigation, treatment and outcome to similar data in other part of the world.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consecutive patients presenting to the Emergency Department with Dyspnea as main complaint
  • 18 years or older

排除标准

  • No acceptance to participate from the patient

结局指标

主要结局

All cause mortality

时间窗: 30 days

All cause mortality will be evaluated 30 days after ED visit.

次要结局

  • All cause rehospitalization(30 days)

研究者

发起方
Hopital Lariboisière
申办方类型
Other
责任方
Principal Investigator
主要研究者

Said LARIBI, MD, PhD.

Principal Investigator

Hopital Lariboisière

研究点 (10)

Loading locations...

相似试验